PCI术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响

发布时间：2018-06-10 19:38

本文选题：辛伐他汀 + 急性冠脉综合征　；参考：《中国药房》2017年12期

【摘要】：目的:探讨经皮冠状动脉介入治疗(PCI)术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响。方法:106例急性冠脉综合征患者随机分为观察组(53例)和对照组(53例)。两组患者PCI术后均口服阿司匹林肠溶片100 mg,每日1次+氯吡格雷片75 mg,每日1次,持续4周;观察组患者于术前15 d每日晚饭前加服辛伐他汀片20 mg。观察两组患者术前和术后6个月总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、IL-18、左室射血分数(LVEF)、冠状动脉再狭窄发生情况及不良反应发生情况。结果:两组患者术前和术后6个月TG、TC、LDL-C和HDL-C水平比较,差异均无统计学意义(P0.05)。术前,两组患者hs-CRP、IL-6、IL-18和LVEF水平比较,差异均无统计学意义(P0.05)。术后6个月,两组患者hs-CRP、IL-6、IL-18和LVEF水平均显著高于同组治疗前,但观察组hs-CRP、IL-6和IL-18均显著低于对照组,LVEF显著高于对照组,差异均有统计学意义(P0.05)。观察组患者冠状动脉再狭窄发生率显著低于对照组,差异有统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生。结论:PCI术前强化辛伐他汀治疗,可有效降低急性冠脉综合征患者术后的心血管炎症反应程度,预防冠状动脉血栓再形成,降低术后冠状动脉再狭窄发生率,改善患者预后,且不增加不良反应的发生。
[Abstract]:Objective: to investigate the effect of intensive simvastatin before percutaneous coronary intervention (PCI) on postoperative indexes in patients with acute coronary syndrome (ACS). Methods 106 patients with acute coronary syndrome were randomly divided into observation group (n = 53) and control group (n = 53). The patients in both groups were given aspirin enteric-coated tablets 100 mg once a day, clopidogrel 75 mg once a day for 4 weeks, and simvastatin 20 mg before supper 15 days before PCI in both groups. Before and 6 months after operation, total cholesterol (TCN), triglyceride (TGG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6) IL-6 / IL-18, left ventricular ejection fraction (LVEFF), coronary artery resuscitation (CAR) were observed in both groups. The incidence of stenosis and adverse reactions. Results: there was no significant difference in the levels of LDL-C and HDL-C between the two groups before and 6 months after operation (P 0.05). Before operation, the levels of IL-18 and LVEF were not significantly different between the two groups. Six months after operation, the levels of IL-18 and LVEF in hs-CRPnl IL-6 and LVEF in the two groups were significantly higher than those in the same group before treatment, but the levels of hs-CRPnIL-6 and IL-18 in the observation group were significantly lower than those in the control group (P 0.05). The incidence of coronary artery restenosis in the observation group was significantly lower than that in the control group (P 0.05). No significant adverse reactions occurred during treatment in both groups. Conclusion intensive simvastatin before PCI can effectively reduce the degree of cardiovascular inflammation, prevent coronary thrombosis, reduce the incidence of coronary restenosis and improve the prognosis of patients with acute coronary syndrome. There was no increase in the incidence of adverse reactions.
【作者单位】：唐山市工人医院心内二科;唐山市工人医院心内一科;唐山市工人医院检验科;唐山市工人医院急诊抢救室;唐山市工人医院妇二科;
【分类号】：R541.4

【相似文献】